最新ニュース Moderna (NASDAQ:MRNA) 株価情報

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Large Cap

News

Movers

APTV

BGNE

BIRK

MRNA

POOL

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？

米製薬大手モデルナ　米国市場を牽引

Moderna Inc

WIIM

Moderna shares are trading higher after the company announced it's receiving ongoing support from the U.S. HHS to accelerate the development of its mRNA-based pandemic influenza vaccines.

<a href="https://www.nbcnews.com/health/health-news/bird-flu-concerns-grow-scientists-race-develop-new-vaccines-rcna187824" title="https://www.nbcnews.com/health/health-news/bird-flu-concerns-grow-scientists-race-develop-new-vaccines-rcna187824">https://www.nbcnews.com/health/health-news/bird-flu-concerns-grow-scientists-race-develop-new-vaccines-rcna187824</a>

Biotech

Contracts

General

'Moderna Says Ongoing Support From U.S. HHS To Accelerate Development Of mRNA-based Pandemic Influenza Vaccines; $590M Award Funded In Whole Or In Part With Federal Funds From HHS, ASPR, BARDA' - NBC News

The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">virus within 24 hours.&nbsp;</a>
What To Know: There have been 67 confirmed human cases of bird flu in the U.S. since 2024 and the CDC<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> says it is</a> "watching the situation carefully and working with states to monitor people with animal exposures."
The CDC's latest H5N1<a href="https://www.cdc.gov/han/2025/han00520.html"> bird flu advisory</a> comes as new cases continue to be revealed. On Wednesday, the CDC confirmed a bird flu infection in a child in the San Francisco area who was not hospitalized and has since recovered. The CDC said it is still investigating how the child was exposed to the virus. 
Read Next: <a href="https://www.benzinga.com/general/health-care/25/01/43041254/unitedhealth-ceo-highlights-hospitals-doctors-pharmas-role-in-soaring-health-care-costs">UnitedHealth CEO Highlights Hospitals, Doctors, Pharma&#8217;s Role In Soaring Health Care Costs</a>&nbsp;
According to a Washington Post<a href="https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/"> report</a>, Nirav Shah, CDC's principal deputy director, said the latest recommendation is meant to accelerate testing rather than increase the number of tests being performed.&nbsp;
Shah said it was prompted by cases in which infected patients were later confirmed to have bird flu, including after being discharged.
Earlier this month, the Louisiana Department of Health reported the first human death in the U.S. related to the H5N1 bird flu virus.
Vaccine Makers: Shares of vaccine-related stocks are on watch as previous bird flu developments have caused shares to spike.&nbsp;
Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company's COVID-19 vaccine.  
Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has a bird flu vaccine in clinical trials<a href="https://www.benzinga.com/general/biotech/24/11/41878334/fda-gives-green-signal-to-novavaxs-covid-19-influenza-combo-vaccine-late-stage-trial"> in addition</a> to a COVID-19-influenza combination vaccine in late-stage clinical trials. 
CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) stock is also on watch as the company has started a phase I/II study on its bird flu vaccine developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>).  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43007213/experts-see-the-fed-on-hold-for-now-if-there-are-any-cuts-at-all-in-2025-after-decembers-sticky-consumer-inflation-report">Interest Rate Cuts &#8216;On Hold&#8230; If There Are Any At All In 2025&#8217; After December&#8217;s Sticky Consumer Inflation Report: Economists&nbsp;</a></li>
</ul>
Photo: Shutterstock

Government

Health Care

CVAC

NVAX

Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 28 unusual trades.
Delving into the details, we found 17% of traders were bullish, while 64% showed bearish tendencies. Out of all the trades we spotted, 24 were puts, with a value of $2,768,045, and 4 were calls, valued at $229,686.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $100.0 for Moderna over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1878.47 with a total volume of 6,225.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $25.0 to $100.0 over the last 30 days.
<h3>Moderna 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737050465_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$52.05</td>
<td>$51.8</td>
<td>$52.0</td>
<td>$85.00</td>
<td>$847.6K</td>
<td>22</td>
<td>178</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.4</td>
<td>$5.35</td>
<td>$5.35</td>
<td>$35.00</td>
<td>$535.0K</td>
<td>2.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$42.15</td>
<td>$41.5</td>
<td>$42.15</td>
<td>$75.00</td>
<td>$316.1K</td>
<td>233</td>
<td>25</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$42.35</td>
<td>$41.0</td>
<td>$42.35</td>
<td>$75.00</td>
<td>$105.8K</td>
<td>233</td>
<td>0</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.6</td>
<td>$12.4</td>
<td>$12.6</td>
<td>$40.00</td>
<td>$99.5K</td>
<td>4.0K</td>
<td>79</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,601,101, the MRNA's price is up by 0.06%, now at $34.79. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 35 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

A Closer Look at Moderna's Options Market Dynamics

Ratings for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $66.5, with a high estimate of $111.00 and a low estimate of $38.00. Observing a downward trend, the current average is 32.24% lower than the prior average price target of $98.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1736967612_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Moderna's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$59.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Moderna's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moderna analyst ratings.</a>
<h2>Discovering Moderna: A Closer Look</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Financial Milestones: Moderna's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Moderna's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.81%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Moderna's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Moderna's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.11%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.08%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Moderna adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Morgan Stanley analyst Matthew Harrison maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Equal-Weight and lowers the price target from $70 to $38.

Price Target

Morgan Stanley Maintains Equal-Weight on Moderna, Lowers Price Target to $38

<h3>Gainers</h3>
<ul>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock increased by 185.6% to $4.47 during Monday's pre-market session. The market value of their outstanding shares is at $6.4 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock moved upwards by 141.42% to $4.08. The market value of their outstanding shares is at $7.0 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 69.84% to $2.14. The company's market cap stands at $8.5 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) stock increased by 38.01% to $7.66. The company's market cap stands at $468.5 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock moved upwards by 34.76% to $127.85. The market value of their outstanding shares is at $13.5 billion. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares rose 34.02% to $1.3. The market value of their outstanding shares is at $16.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock fell 31.4% to $4.1 during Monday's pre-market session. The company's market cap stands at $237.3 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares fell 27.47% to $0.59. The company's market cap stands at $2.9 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares decreased by 21.51% to $2.08. The market value of their outstanding shares is at $4.6 million. </li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares decreased by 21.02% to $33.37. The market value of their outstanding shares is at $12.8 billion. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock fell 19.4% to $1.33. The market value of their outstanding shares is at $39.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 19.19% to $0.15. The market value of their outstanding shares is at $11.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

AIRS

ATPC

DYAI

GTBP

ITCI

KAPA

NAYA

PHIO

SAGE

SLRX

12 Health Care Stocks Moving In Monday's Pre-Market Session

Traders adopted a cautious approach on Monday as they awaited two critical inflation reports due later this week, seeking clarity on Federal <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42953940/tuesdays-producer-inflation-report-could-stoke-market-volatility-as-fed-path-remains-unclear">Reserve interest rate policy. </a>
Additionally, the kickoff of earnings season, led by major banks on Wednesday, added to <a href="https://www.benzinga.com/markets">the market&#8217;s subdued tone.</a>
The S&amp;P 500 and Nasdaq 100 edged lower, continuing Friday&#8217;s downturn sparked by unexpectedly strong jobs data. The lack of &#8220;buy-the-dip&#8221; enthusiasm in the tech-heavy indices signaled lingering uncertainty among investors.
In contrast, the Dow Jones Industrial Average eked out a gain, buoyed by a rally in energy stocks. Rising oil prices provided a key lift, as West Texas Intermediate (WTI) crude oil surged over 3% to approach $78 per barrel — a level last seen in mid-August 2024. The spike followed U.S. sanctions on Russian crude exports announced on Friday, which shifted market expectations around supply and demand.
Treasury yields extended their ascent, with the 10-year yield climbing to 4.79% and the 30-year yield rising to 4.97%, reflecting heightened expectations for tighter monetary policy. Bank of America Securities launched a bombshell indicating rising risks towards a rate hike as the next Fed move.
Commodity markets saw mixed action. Gold endured its sharpest daily loss in nearly a month, falling more than 1% as rising yields weighed on the precious metal. Meanwhile, copper staged a modest rebound, gaining 0.8% after a 0.5% decline last Friday.
Cryptocurrencies faced renewed volatility, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) plunging 3% to dip below $92,000, briefly touching a two-month low. The ripple effects extended to crypto-linked equities: MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) slid more than 3%, while Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) dropped nearly 4%.
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg. %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,144.04</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,822.92</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,183.39</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,739.92</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.1% lower to $579.98.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.7% to $422.03.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.6% to $504.44.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dipped 0.3% to $216.19.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2.3%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Major oil &amp; gas giants rallying on Monday include Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>), up 5%, Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) up 3.9%, and Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) up 3.5%.</li>
<li>Health insurance companies surged after a government proposal suggested increased payments for Medicare Advantage plans in 2026, lifting sentiment across the sector.</li>
<li>Shares of Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 7.8%, CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) followed closely with a 6.9% jump, while UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) saw a 4.8% increase.+</li>
<li>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dropped 2.7% to $132.19 as the AI chipmaker urged President-elect Donald Trump to oppose Biden administration regulations on AI technology. Meanwhile, HSBC cut its price target from $195 to $185 but reaffirmed its Buy rating.</li>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) plummeted 20% after projecting 2025 revenue of $1.5 billion to $2.5 billion, missing analysts&#8217; estimates of $2.92 billion. The company also announced it would fast-track its cost-cutting measures.</li>
<li>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) fell 12% as authorities investigated whether equipment from its subsidiary, Southern California Edison, played a role in sparking the Hurst fire in Los Angeles.</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42948649/goldman-sachs-warns-of-90-oil-risk-trump-may-not-ease-sanctions-once-he-takes-office">Oil Could Hit $90, Goldman Sachs Says: &#8216;Trump May Not Ease Sanctions&#8217; On Russia</a></li>
</ul>
Photo: Ryan DeBerardinis via Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

COIN

SPDR Dow Jones Industrial Average ETF Trust

MSTR

NVDA

Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 150 points on Monday.
The Dow traded up 0.64% to 42,206.46 while the NASDAQ dipped 0.79% to 19,010.47. The S&amp;P 500 also fell, dropping, 0.11% to 5,820.34.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/42944267/how-to-earn-500-a-month-from-fastenal-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Fastenal Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 1.6% on Monday.
In trading on Monday, utilities shares tumbled by 1.8%.
Top Headline
U.S. consumer inflation expectations for the year ahead came in unchanged at 3% in December, the same as in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares shot up 426% to $6.43 after the company reported promising results of second cohort from its ongoing clinical study of PH-762.</li>
<li>Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)got a boost, surging 159% to $4.04. Salarius Pharmaceuticals and Decoy Therapeutics announced a definitive merger agreement.</li>
<li>Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares were also up, gaining 34% to $127.42 after Johnson &amp; Johnson agreed to acquire the company for $132.00 per share in cash for a total equity value of approximately $14.6 billion.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dropped 20% to $33.67 after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion.</li>
<li>Shares of Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) were down 18% to $132.09 after issuing mixed fourth-quarter and FY24 guidance.</li>
<li>Comtech Telecommunications Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) was down, falling 48% to $2.15 after the company announced downbeat quarterly results.</li>
</ul>
Commodities In commodity news, oil traded up 2.7% to $78.66 while gold traded down 1.4% at $2,677.60.
Silver traded down 3.1% to $30.345 on Monday, while copper rose 0.4% to $4.3195.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 declined 0.55%, Germany's DAX 40 fell 0.41% and France's CAC 40 dipped 0.30%. Spain's IBEX 35 Index fell 0.28%, while London's FTSE 100 slipped 0.29%.
Asia Pacific Markets
Asian markets closed lower on Monday, with China's Shanghai Composite Index falling 0.25%, Hong Kong's Hang Seng Index declining 1% and India's BSE Sensex falling 1.36%.
Economics
U.S. consumer inflation expectations for the year ahead came in unchanged at 3% in December, the same as in the previous month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42947348/tesla-to-rally-around-9-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Earnings

Equities

Eurozone

Intraday Update

Trading Ideas

CMTL

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Monday.
The Dow traded up 0.13% to 41,992.95 while the NASDAQ dipped 1.42% to 18,888.78. The S&amp;P 500 also fell, dropping, 0.70% to 5,786.44.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/42944267/how-to-earn-500-a-month-from-fastenal-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Fastenal Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 2.2% on Monday.
In trading on Monday, utilities shares tumbled by 1.9%.
Top Headline 
Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) confirmed that Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares shot up 418% to $8.76 after the company reported promising results of second cohort from its ongoing clinical study of PH-762.</li>
<li>Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)got a boost, surging 277% to $5.87. Salarius Pharmaceuticals and Decoy Therapeutics announced a definitive merger agreement.</li>
<li>Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares were also up, gaining 35% to $127.72 after Johnson &amp; Johnson agreed to acquire the company for $132.00 per share in cash for a total equity value of approximately $14.6 billion.</li>
</ul>
<ul>
<li>Equities Trading DOWN</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dropped 22% to $33.13 after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion.</li>
<li>Shares of Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) were down 20% to $129.03 after issuing mixed fourth-quarter and FY24 guidance.</li>
<li>Comtech Telecommunications Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) was down, falling 47% to $2.1901 after the company announced downbeat quarterly results.</li>
</ul>
Commodities In commodity news, oil traded up 3.1% to $78.93 while gold traded down 1.1% at $2,685.60.
Silver traded down 3% to $30.37 on Monday, while copper rose 0.8% to $4.3365.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.45%, Germany's DAX 40 fell 0.26% and France's CAC 40 dipped 0.11%. Spain's IBEX 35 Index fell 0.23%, while London's FTSE 100 slipped 0.19%.
Asia Pacific Markets
Asian markets closed lower on Monday, with China's Shanghai Composite Index falling 0.25%, Hong Kong's Hang Seng Index declining 1% and India's BSE Sensex falling 1.36%.
Economics
Data on consumer inflation expectations will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42947348/tesla-to-rally-around-9-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

BIIB

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge

<ul>
<li>NVDA</li>
<li>AMD</li>
<li>TSLA</li>
<li>MSTR</li>
<li>MRNA</li>
<li>$BTC</li>
<li>DJT</li>
<li>GAP</li>
<li>QQQ</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

TSLA

Top 10 Trending Stocks On WallStreetBets As Of January 13, 2025 (Via Swaggy Stocks)

Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged on Monday after the company announced business updates and progress <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/ac42940864/moderna-provides-business-and-pipeline-updates-at-43rd-annual-j-p-morgan-healthcare-conference" rel="noreferrer noopener">across its pipeline</a>. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.
The company will present at the 43rd&nbsp;Annual J.P. Morgan Healthcare Conference.
In September, Moderna unveiled key updates at its annual R&amp;D Day by reducing annual R&amp;D spending by $1.1 billion by 2027, enabling a focus on&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40863528/moderna-faces-analyst-downgrades-amid-revised-r-d-restructured-strategy-and-delayed" rel="noreferrer noopener">ten prioritized products</a>.
The company expects R&amp;D expenses to fall from $4.8 billion in 2024E to $3.6 billion—$3.8 billion in 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a>
The strategy, expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years.
In fiscal year 2024,&nbsp;Moderna achieved preliminary product sales of approximately $3 billion-3.1 billion, comprising $1.7 billion in the U.S. and $1.3 to 1.4 billion in the rest of the World.
This includes more than $3 billion in Spikevax sales and minimal sales from mRESVIA, its RSV Vaccine. Cash, cash equivalents, and investments at year-end 2024 were approximately $9.5 billion.
Moderna is accelerating and expanding its previous cost efficiency and prioritization programs and now projects cash cost reductions of $1.0 billion in 2025.
The company expects an additional $0.5 billion in potential cash cost savings in 2026. In September, the company announced its plans to reduce annual R&amp;D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.
Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025 compared to the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.95 billion</a>, mostly in the second half of the year, primarily due to Spikevax and mRESVIA vaccine sales. Earlier, Moderna projected revenues of $2.5 to $3.5 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">by 2025</a>.
The company expects to end 2025 with approximately $6.0 billion in cash and investments.
Moderna reported third-quarter revenue of $1.83 billion, compared with $1.83 billion a year earlier, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41854205/modernas-q3-earnings-beat-overshadowed-by-vaccine-demand-slowdown-and-market-share-concerns-analysts-warn" rel="noreferrer noopener">consensus of $1.25 billion</a>.
The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.
Price Action: At last check on Monday, MRNA stock was down 19.20% to $34.13.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42939311/wayfair-expands-google-cloud-partnership-to-tap-ai-for-cost-cuts-and-efficiency" target="_blank" rel="noreferrer noopener">Wayfair Expands Google Cloud Partnership To Tap AI For Cost Cuts And Efficiency</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Guidance

Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives

LULU: 7% &#x7C; <a href="https://www.benzinga.com//node/42940242">Lululemon shares are trading higher after the company raised its Q4 guidance</a>
&nbsp;
MRNA: -19% &#x7C; <a href="https://www.benzinga.com//node/42941896">Moderna shares are trading lower after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion.</a>
&nbsp;
XHG: 73% &#x7C; <a href="https://www.benzinga.com//node/42928773">XChange TEC.INC Say Yong Zhang Resigned As CEO And Chairman Of Board</a>
&nbsp;
&nbsp;

LULU

Market-Moving News for January 13th

Moderna achieved 2024 product sales in the range of approximately $3.0 to 3.1 billion (unaudited), comprising $1.7 billion in the U.S. and $1.3 to 1.4 billion in Rest of World.
This includes more than $3.0 billion in Spikevax&#xAE; sales and minimal sales from mRESVIA. Cash, cash equivalents and investments at year-end 2024 were approximately $9.5 billion. Full financial details will be reported in connection with the Company's earnings call on February 14, 2025.

Moderna Expects Milestones Across 10 Prioritized Programs, Including Up To Three Potential 2025 Approvals And Six Registrational Data Readouts

Moderna shares are trading lower after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion.

Moderna Expects To Reduce 2025 Cash Cost Expenses By $1B With Plan For Additional 2026 Cost Reductions Of $0.5B

Moderna is accelerating and expanding its previous cost efficiency and prioritization programs and now projects cash cost reductions of $1.0 billion (including cost of sales, research and development, and selling, general &amp; administrative expense) in 2025.
The Company expects an additional $0.5 billion in potential cash cost savings in 2026. Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025, mostly in the second half of the year, primarily due to Spikevax and mRESVIA vaccine sales. The Company expects to end 2025 with cash and investments of approximately $6.0 billion.

Moderna  Updates 2025 Expected Revenue Range To $1.5B - $2.5B, Est $2.951B

The U.S. reported its <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">first human death</a> from the H5 bird flu strain this week, causing a spike in vaccine developer stocks Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html" target="_blank" rel="noreferrer noopener"> an update </a>on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak. 
CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
See Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax (NVAX) Stock Is Rising</a>
<h3 class="wp-block-heading">Vaccine Providers in the Limelight</h3>
In the U.S., vaccines against H5N1 are already stockpiled. Approved shots include those from Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), CSL Seqirus, and ID Biomedical Corporation of Quebec, a subsidiary of GlaxoSmithKline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), which collectively secured $72 million in funding from the U.S. health department in October to boost the production of bird flu vaccines. These traditional vaccines, developed years ago, target older H5N1 strains but are expected to offer some protection.
Moderna, backed by $176 million from the U.S. government's BARDA, is working on an updated mRNA H5N1 vaccine. Other players, including Pfizer and GSK (in collaboration with CureVac), are testing similar candidates.
<h3 class="wp-block-heading">ETFs in Focus</h3>
For investors who want to play the trend but are wary of choosing individual biotech stocks, here are three ETFs that offer diversified exposure to the biotech companies leading the vaccine efforts. With a mix of traditional and mRNA vaccine developers in focus, these funds could benefit as the world prepares for a potential bird flu pandemic.
iShares Genomics Immunology and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NYSE">IDNA</a>) tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index, and has already gained 2.5% so far this year. The fund has an expense ratio of 0.47%, and $129.97 million in assets under management (AUM). The fund has currently invested 4.48% of its assets in Moderna. Sanofi, GSK and Novavax are also part of its portfolio of 51 equity holdings.
First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>) derives its investment strategy from the Nasdaq US Benchmark Index, and has an expense ratio of 0.60%. Pfizer is one of its top holdings, with 7.28% of assets allocated to it.
SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) mirrors the S&amp;P&nbsp;Biotechnology Select Industry&nbsp;Index, and charges a 0.35% expense ratio. Out of its present AUM of $6.37 billion, Moderna holds 2.58%. Almost 100% of its holdings are exposed to the biotechnology sector, with only about 0.04% invested in the pharmaceutical sector.
<h3 class="wp-block-heading">The Bird Flu Menace </h3>
The bird flu scare in humans ratcheted higher in late 2024 when a 13-year-old girl in Canada fell critically ill with H5N1 and required a ventilator. Around the same time, the U.S. reported its first severe case in an elderly patient in Louisiana.
Health experts warn that vigilance is key to preventing mutations that could trigger a pandemic. While the technology to develop vaccines quickly is available, governments may need to fund large-scale clinical trials in advance to ensure rapid distribution in case of a health emergency.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling">Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</a></li>
</ul>
Photo: Shutterstock.

Sector ETFs

FTXH

IDNA

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

Moderna shares are trading lower after UBS cut its price target on the stock from $108 to $96.

UBS analyst Eliana Merle maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Buy and lowers the price target from $108 to $96.

UBS Maintains Buy on Moderna, Lowers Price Target to $96

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on January 13 and set a price target of $40.00. The comp...

RBC Capital Keeps Their Hold Rating on Moderna (MRNA)

How is SPY stock faring? The SPDR S&P 500 ETF Trust  is up 2.83% in the past 5 days and has risen about 24.16% over the past year. According to Tip...

SPY ETF News, 1/16/2025

Most shorted S&P 500 stocks in December

Best and worst S&P 500 performers so far in 2025: MRNA, WBA, MU, ON, and more

Berenberg Bank analyst Harry Gillis maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $33.00. The co...

Berenberg Bank Sticks to Its Hold Rating for Moderna (MRNA)

The U.S. Department of Health and Human Services has awarded Moderna (MRNA) $590M to "advance the late-stage development of its mRNA bird flu vacci...

Moderna awarded $590M by U.S. for bird flu vaccine development, Reuters reports

Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of mRNA-based pa...

Moderna confirms $590M award by U.S. for bird flu vaccine development

Moderna gets $590M HHS contract to develop bird flu vaccine - report

Moderna gets $590M HHS contract to develop mRNA pandemic flu vaccines

The U.S. government is giving pharmaceutical company Moderna ($MRNA) $590 million in new money to accelerate development of a vaccine against H5N1 ...

Moderna (MRNA) Secures $590 Million to Accelerate Bird Flu Vaccine

CHTR

ENPH

FOXA

FSLR

PARA

PLTR

QRVO

REGN

SMCI

SPXU

SWKS

UPRO

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

Events

Moderna to Present at Upcoming Conferences in December 2024

Legal

DexCom, Orthofix, Spire Global, and Moderna Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Annual Changes to the Nasdaq-100 Index®

Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Moderna Announces Updates on Pandemic Influenza Program

AXON

CARM

FHTX

ILMN

NDAQ

OFIX

OMGA

SANA

SPIR

Morgan Stanley

B of A Securities

JP Morgan

Piper Sandler

先週の株価下落率上位10社に名を連ねたのは以下の銘柄だ。投資家はこれらの銘柄を保有しているだろうか？
<ol>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) の株価は、同社が市場予想を下回る<a class="ticker" href="https://www.benzinga.com//node/39523397" target="_blank" rel="noopener noreferrer">第3四半期決算を発表し</a>、2024年の業績予想を引き下げたことから24.12%急落した。アナリストは、株の<a class="ticker" href="https://www.benzinga.com/quote/wba/analyst-ratings" target="_blank" rel="noopener noreferrer">株価予想を引き下げている</a>。</li>
<li>Floor &amp; Decor Holdings, Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)の株は13.41%下落し、これは5月の予定住宅販売経済指標が期待を下回ったことに対するリアクションかもしれない。</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) の株価は同社のRSVワクチン接種の効果が<a class="ticker" href="https://www.benzinga.com//node/39508239" target="_blank" rel="noopener noreferrer">50%という結果</a>から11.76%下がった。</li>
<li>Birkenstock Holding Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) の株は同社が1千4百万株までの株式オファリングを<a href="https://www.benzinga.com//node/39467369" target="_blank" rel="noopener noreferrer">株主買い戻しによって行う</a>と発表したことで10.86%下落した。</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) の株は9.70%下落した。</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) の株価は同社が同社の<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">決算予想を下方修正した</a>後、9.19%下がった。</li>
<li>JD.Com, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) の株価は、米国が中国企業への<a class="ticker" href="https://www.benzinga.com//node/39521291" target="_blank" rel="noopener noreferrer">投資を抑制する規則を発表した</a>ことで8.89%下落した。</li>
<li>Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) の株価は8.02%急落した</li>
<li>International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) の株価はSuzano SA（NYSE:SUZ）が同社の<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">買収取引</a>を進展させないと発表したことに伴い、7.98%下落した。</li>
<li>Micron Technology Inc.の（NASDAQ:MU）株は、第3四半期の決算と第4四半期の見通し<a href="https://www.benzinga.com//node/39520174" target="_blank" rel="noreferrer noopener">を発表したことを受け、先週7.62%急落</a>した。</li>
</ol>

Comments

Moderna

ニュース

最新ニュース Moderna (NASDAQ:MRNA) 株価情報

月曜日, 7 01, 2024

ニュース

パートナーシップ

ベンジンガ・グローバル